Abstract Number: 1984 • ACR Convergence 2022
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population. It is hence…Abstract Number: 0707 • ACR Convergence 2022
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…Abstract Number: 2199 • ACR Convergence 2022
Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…Abstract Number: 0722 • ACR Convergence 2022
Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role…Abstract Number: 2216 • ACR Convergence 2022
JAK Inhibitors and Risk of Cancer
Background/Purpose: Recent concerns have been raised about potential increase of cancer risk under JAK inhibitors (JAKi) especially tofacitinib. Discrepant findings have been given by randomized…Abstract Number: 0723 • ACR Convergence 2022
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Background/Purpose: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib…Abstract Number: 0862 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…Abstract Number: 1112 • ACR Convergence 2022
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…Abstract Number: 1199 • ACR Convergence 2022
Validation of New Medication User Definitions in Single-Specialty EHR Data
Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…Abstract Number: 1374 • ACR Convergence 2022
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…Abstract Number: 1429 • ACR Convergence 2022
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…Abstract Number: 1546 • ACR Convergence 2022
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- Next Page »